MEDIA RELEASE PR38598
Kendle Receives Approval From Indian Government to Proceed With Development of Operations
Center in Special Economic Zone
CINCINNATI, Mar. 4 /PRNewswire-AsiaNet/ --
Company's continued investment in Asia/Pacific expands its global
footprint to meet customer demands
Kendle (Nasdaq: KNDL), a leading, global full-service clinical research
organization, today announced the Company has received approval from Indian
authorities to proceed with development of a new operations center in a
Special Economic Zone (SEZ) in the upcoming Ahmedabad-Gandhinagar Knowledge
Corridor. The new SEZ center represents an important and strategic investment
for Kendle and demonstrates the Company's commitment to further invest in
Asia/Pacific to meet customer needs. The new unit is expected to be
operational by mid April.
"Continued expansion throughout the Asia/Pacific region is crucial to the
future growth of Kendle," said Stephen Cutler, PhD, Senior Vice President and
Chief Operating Officer. "Our increased capacity in the region will allow us
to better meet the growing demands of our customers who are seeking to
capitalize on India's rapidly expanding high-quality biopharmaceutical
capabilities. The new SEZ operations center will be ideally suited to deliver
best-in-class services to our customers seeking high-quality, innovative and
cost-effective solutions for their clinical development needs."
The SEZ operations center will be a high-end, world-class center of
excellence focusing on quality delivery of clinical data management, medical
writing, pharmacovigilance/safety, biostatistics/programming and other
knowledge processing-related services. These clinical support services will
be integrated under one roof, providing an efficient operations hub for the
region.
Kendle's SEZ operations center initially will house approximately 50
associates and is expected to scale up to approximately 300 associates in the
near term. The unit is positioned to further expand very quickly if necessary
to meet customer demand. The unique geography of the unit, in close proximity
to multiple universities as well as the modern city of Ahmedabad, provides a
vast untapped talent pool ideal for building and expanding a high-tech
workforce.
Kendle's expansion in the quickly maturing India market reflects the
growing importance of the country to the global clinical research market.
With more than one billion people, a growing and improving research
infrastructure, an efficient and evolving regulatory setting, favorable
intellectual property laws, a large pool of medical professionals and
established research credentials, India is quickly becoming a world power in
clinical research. By 2012, analysts project that more than 65 percent of all
FDA-regulated trials will take place outside the United States. This is
reflected in the Indian biotechnology market, which is expected to grow at a
compounded annual growth rate of 30 percent, and the Indian CRO market, which
is expected to see growth of 49 percent annually.
Kendle currently operates throughout the Asia/Pacific region from its
offices in Ahmedabad and New Delhi, India; Beijing, Hong Kong and Shanghai,
China; Kuala Lumpur, Malaysia; Bangkok, Thailand; Manila, Philippines;
Singapore; and Sydney and Melbourne, Australia.
About Kendle
Kendle International Inc. (Nasdaq: KNDL) is a leading global clinical
research organization providing the full range of early- to late-stage
clinical development services for the world's biopharmaceutical industry. Our
focus is on innovative solutions that reduce cycle times for our customers
and accelerate the delivery of life-enhancing drugs to market for the benefit
of patients worldwide. As one of the world's largest global providers of
Phase I-IV services, we offer experience spanning more than 100 countries,
along with industry-leading patient access and retention capabilities and
broad therapeutic expertise, to meet our customers' clinical development
challenges.
Additional information and investor kits are available upon request from
Kendle, 441 Vine Street, Suite 500, Cincinnati, OH 45202 or from the
Forward-Looking Statements
Certain statements and information contained in this press release may be
deemed to be forward-looking statements under federal securities laws and the
provisions of the Private Securities Litigation Reform Act of 1995 and Kendle
intends that such forward-looking statements be subject to the safe-harbor
created thereby. All such forward-looking statements, including the
statements contained herein regarding anticipated trends from Kendle's
opening of the Special Economic Zone Operations Center in Ahmedabad, India
are based largely on management's expectations and are subject to and
qualified by risks and uncertainties that could cause actual results to
differ materially from those expressed or implied by such statements. These
risks and uncertainties include those risks as detailed from time to time in
Kendle's Annual Report on Form 10-K as well as periodic reports filed with
the SEC. All information in this press release is current as of March 3,
2010. The Company undertakes no duty to update any forward-looking statement
to conform the statement to actual results or changes in the Company's
expectations.
SOURCE: Kendle International Inc.
CONTACT: Michael Lawson, Investors,
+1-513-763-1992, or
Lori Dorer, Media,
+1-513-345-1685
NEWS 
